FTC Urged To Investigate AbbVie’s IP Strategy On Humira
US Representatives Suggest Biosimilar Adalimumab Competition Delayed From 2017 To 2023
AbbVie delayed biosimilar competition to Humira “for far longer than warranted” and may have “engaged in other anti-competitive conduct to maintain its market share and pricing power” for the adalimumab brand, according to members of the US House of Representatives’ committee on oversight and reform. The US Federal Trade Commission has been urged to open a formal inquiry into the originator’s conduct.
You may also be interested in...
In the latest twist in the tussle between Alvotech and AbbVie over Humira intellectual property, the originator has sued the Icelandic firm for a second time in a court in Illinois, in an attempt to enforce almost 60 patents that it says Alvotech has previously declined to litigate.
Over the past five years, around a tenth of the US generics market’s total value has been ceded by oral solid dose generics to other formulations, IQVIA’s Doug Long told the AAM’s “Access!” annual meeting at the end of May.
As it begins to roll out its Yuflyma higher-strength adalimumab biosimilar in Europe, Celltrion has reported positive one-year data from a Phase III trial for the 100mg/ml Humira rival.